Stockscreener 앱 받기
3.80
2.81%
-0.11
시장 영업 전:
3.69
-0.11
-2.89%
Can-Fite Biopharma Ltd ADR 주식(CANF)의 최신 뉴스
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology - Sahm
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
CANF Stock Price, Quote & Chart - ChartMill
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANFCan-Fite Biopharma Ltd ADR Stock Price and Quote - Finviz
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication By Investing.com - Investing.com South Africa
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Published on: 2026-01-10 23:44:28 - ulpravda.ru
Curious about the most active stocks on Friday? - ChartMill
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Sahm
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Top movers in Monday's session - ChartMill
Jason Kolbert Analyst Performance at D. Boral Capital - MarketBeat
Stock Ratings | Morgan Stanley maintained its "neutral" rating on Palantir Technologies (PLTR) and raised its price target from $155 to $205. - Sahm
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Unusual volume stocks in Friday's session - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Which stocks are gapping on Tuesday? - ChartMill
0.05%
0.74%
자본화:
|
볼륨(24시간):